

CAR-T Cell Therapy for Acute Lymphoblastic Leukemia Relapsed and Refractory Disease

Current Hematologic Malignancy Reports

13, 396-406

DOI: [10.1007/s11899-018-0470-x](https://doi.org/10.1007/s11899-018-0470-x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	B Cell Siglecsâ€“News on Signaling and Its Interplay With Ligand Binding. <i>Frontiers in Immunology</i> , 2018, 9, 2820.	2.2	71
2	Approach to the Adult Acute Lymphoblastic Leukemia Patient. <i>Journal of Clinical Medicine</i> , 2019, 8, 1175.	1.0	28
3	Driving the CAR to the Bone Marrow Transplant Program. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 561-569.	1.2	10
4	Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	178
5	The Emergence of Universal Immune Receptor T Cell Therapy for Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 176.	1.3	64
6	CAR T Cell Therapy for Hematological Malignancies. <i>Current Medical Science</i> , 2019, 39, 874-882.	0.7	22
7	The Emergence of Natural Killer Cells as a Major Target in Cancer Immunotherapy. <i>Trends in Immunology</i> , 2019, 40, 142-158.	2.9	218
8	The effect of graftâ€“versusâ€“host disease on outcomes after allogeneic stem cell transplantation for refractory lymphoblastic lymphoma in children and young adults. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28129.	0.8	5
9	Central Nervous System Relapse After Stem Cell Transplantation in Adolescents and Young Adults with Acute Lymphoblastic Leukemia: A Single-Institution Experience. <i>Journal of Adolescent and Young Adult Oncology</i> , 2020, 9, 166-171.	0.7	6
11	Colorectal Cancer Immunotherapy: Options and Strategies. <i>Frontiers in Immunology</i> , 2020, 11, 1624.	2.2	207
12	Immunotherapy for Metastatic Prostate Cancer: Current and Emerging Treatment Options. <i>Urologic Clinics of North America</i> , 2020, 47, 487-510.	0.8	10
13	Role of Allogeneic HCT as Postremission Therapy for Transplant-Eligible Adult Lymphoblastic Leukemia/Lymphoma After Frontline Hyper-CVAD. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 690-696.	0.2	1
14	A Holistic Perspective: Exosomes Shuttle between Nerves and Immune Cells in the Tumor Microenvironment. <i>Journal of Clinical Medicine</i> , 2020, 9, 3529.	1.0	10
15	Concise review on optimized methods in production and transduction of lentiviral vectors in order to facilitate immunotherapy and gene therapy. <i>Biomedicine and Pharmacotherapy</i> , 2020, 128, 110276.	2.5	21
16	Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions. <i>Journal of Hematology and Oncology</i> , 2020, 13, 70.	6.9	100
17	Quantitative Control of Gene-Engineered T-Cell Activity through the Covalent Attachment of Targeting Ligands to a Universal Immune Receptor. <i>Journal of the American Chemical Society</i> , 2020, 142, 6554-6568.	6.6	36
18	Use of CAR-T cell therapy, PD-1 blockade, and their combination for the treatment of hematological malignancies. <i>Clinical Immunology</i> , 2020, 214, 108382.	1.4	40
19	Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer. <i>Cells</i> , 2020, 9, 561.	1.8	281

#	ARTICLE	IF	CITATIONS
20	T-Cell Gene Therapy in Cancer Immunotherapy: Why It Is No Longer Just CARs on The Road. <i>Cells</i> , 2020, 9, 1588.	1.8	20
21	How I treat relapsed acute lymphoblastic leukemia in the pediatric population. <i>Blood</i> , 2020, 136, 1803-1812.	0.6	90
22	Is Hematopoietic Stem Cell Transplantation Required to Unleash the Full Potential of Immunotherapy in Acute Myeloid Leukemia?. <i>Journal of Clinical Medicine</i> , 2020, 9, 554.	1.0	10
23	CAR-T Cell Therapy in Cancer: Tribulations and Road Ahead. <i>Journal of Immunology Research</i> , 2020, 2020, 1-11.	0.9	49
24	Exploring the Dilemma of Allogeneic Hematopoietic Cell Transplantation after Chimeric Antigen Receptor T Cell Therapy: To Transplant or Not?. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e183-e191.	2.0	25
25	Pseudoprogression of extramedullary disease in relapsed acute lymphoblastic leukemia after CAR T-cell therapy. <i>Immunotherapy</i> , 2021, 13, 5-10.	1.0	10
26	Temporal trends in childhood cancer survival in Egypt, 2007 to 2017: A large retrospective study of 14â€‰%â€‰808 children with cancer from the Children's Cancer Hospital Egypt. <i>International Journal of Cancer</i> , 2021, 148, 1562-1574.	2.3	8
27	Time to Get Turned on by Chemical Biology. <i>ChemBioChem</i> , 2021, 22, 814-817.	1.3	3
28	Cytotoxic CD8+ T cells in cancer and cancer immunotherapy. <i>British Journal of Cancer</i> , 2021, 124, 359-367.	2.9	590
29	Have CD19-directed immunotherapy and haploidentical hematopoietic cell transplantation transformed pediatric B-cell acute lymphoblastic leukemia into a chronic disease?. <i>Oncolmmunology</i> , 2021, 10, 1956125.	2.1	0
31	Use of Blinatumomab in Acute Lymphoblastic Leukemia in Municipal Healthcare: A Case Report. <i>Klinicheskaya Onkogematologiya/Clinical Oncohematology</i> , 2021, 14, 198-203.	0.1	1
32	Siglec-6 is a target for chimeric antigen receptor T-cell treatment of chronic lymphocytic leukemia. <i>Leukemia</i> , 2021, 35, 2581-2591.	3.3	11
33	Anti-CD19 CAR-T cell therapy bridge to HSCT decreases the relapse rate and improves the long-term survival of R/R B-ALL patients: a systematic review and meta-analysis. <i>Annals of Hematology</i> , 2021, 100, 1003-1012.	0.8	21
34	Perspectives for the Use of CAR-T Cells for the Treatment of Multiple Myeloma. <i>Frontiers in Immunology</i> , 2021, 12, 632937.	2.2	12
35	Acute Lymphoblastic Leukemia in Adolescents and Young Adults. , 0, , .		0
36	Introductory Chapter: A Brief History of Acute Leukemias Treatment. , 0, , .		0
37	Genetic Mechanism of Leukemia Relapse Following CD19 Chimeric Antigen Receptor T Cell Therapy. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2021, , .	0.7	1
38	The TRAIL in the Treatment of Human Cancer: An Update on Clinical Trials. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 628332.	1.6	73

#	ARTICLE	IF	CITATIONS
39	Chimeric Antigen Receptor Design and Efficacy in Ovarian Cancer Treatment. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3495.	1.8	9
40	KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. <i>Blood</i> , 2021, 138, 11-22.	0.6	90
41	MicroRNA-325 inhibits the proliferation and induces the apoptosis of T-cell acute lymphoblastic leukemia cells in a BAG2-dependent manner. <i>Experimental and Therapeutic Medicine</i> , 2021, 21, 631.	0.8	5
42	Therapeutic Targeting of the Leukaemia Microenvironment. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6888.	1.8	16
43	Phenolic Compounds – An Emerging Group of Natural Compounds against Leukaemia: in vitro, in vivo and Clinical Applications. <i>Biochemistry</i> , 0, , .	0.8	0
44	KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. <i>Lancet</i> , The, 2021, 398, 491-502.	6.3	315
45	Central nervous system (CNS) involvement has an adverse impact on survival in newly diagnosed adult acute lymphoblastic leukemia (ALL) assessed by flow cytometry. <i>Leukemia and Lymphoma</i> , 2021, 62, 3264-3270.	0.6	3
46	Cell and molecular level of strategy of COVID-19 to induce immunodeficiency. Possible therapeutic solutions. <i>Zhurnal Mikrobiologii Epidemiologii I Immunobiologii</i> , 2021, 98, 450-467.	0.3	2
47	Case Report: Multi-Omics Analysis and CAR-T Treatment of a Chronic Myeloid Leukemia Blast Crisis Case 5 Years After the Discontinuation of TKI. <i>Frontiers in Oncology</i> , 2021, 11, 739871.	1.3	7
48	Conditional control of chimeric antigen receptor T-cell activity through a destabilizing domain switch and its chemical ligand. <i>Cytotherapy</i> , 2021, 23, 1085-1096.	0.3	2
49	Novel TCR-like CAR-T cells targeting an HLA-A*0201-restricted SSX2 epitope display strong activity against acute myeloid leukemia. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 23, 296-306.	1.8	12
50	Natural Killer Cells in Cancer and Cancer Immunotherapy. <i>Cancer Letters</i> , 2021, 520, 233-242.	3.2	19
51	Innate and adaptive immunity in cancer. , 2022, , 19-61.		0
52	Interleukin-37 improves T-cell-mediated immunity and chimeric antigen receptor T-cell therapy in aged backgrounds. <i>Aging Cell</i> , 2021, 20, e13309.	3.0	14
53	Clinical Trials with Cytokine-Induced Killer Cells and CAR-T Cell Transplantation for Non-small Cell Lung Cancer Treatment. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1292, 113-130.	0.8	5
54	Current Management and New Developments in the Treatment of ALL. <i>Cancer Treatment and Research</i> , 2021, 181, 75-96.	0.2	0
55	Mediastinal tumours and pseudo-tumours: a comprehensive review with emphasis on multidisciplinary approach. <i>European Respiratory Review</i> , 2021, 30, 200309.	3.0	12
56	Chimeric Antigen Receptor T-Cell Immunotherapy for Cancer. , 2020, , .		1

#	ARTICLE	IF	CITATIONS
57	Chimeric Antigen Receptor-Engineered T-Cells - A New Way and Era for Lymphoma Treatment. Recent Patents on Anti-Cancer Drug Discovery, 2020, 14, 312-323.	0.8	2
58	Immunotherapy and Radiosurgery. , 2020, , 423-436.		0
60	Clinical determinants of relapse following CAR-T therapy for hematologic malignancies: Coupling active strategies to overcome therapeutic limitations. Current Research in Translational Medicine, 2022, 70, 103320.	1.2	9
61	Newly Found Peacekeeper: Potential of CD8+ Tregs for Graft-Versus-Host Disease. Frontiers in Immunology, 2021, 12, 764786.	2.2	5
62	Modeling and simulation of the IL-36 cytokine and CAR-T cells interplay in cancer onset. International Journal of Modeling, Simulation, and Scientific Computing, 0, , .	0.9	0
63	Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma. Future Oncology, 2022, 18, 277-289.	1.1	20
64	An impedimetric immunosensor for the selective detection of CD34+ T-cells in human serum. Sensors and Actuators B: Chemical, 2022, 356, 131306.	4.0	8
65	Off-the-shelf immunotherapies for multiple myeloma. Seminars in Oncology, 2022, 49, 60-68.	0.8	4
66	Efficiency of anti-VEGF therapy in central nervous system AML relapse: A case report and literature review. Clinical Case Reports (discontinued), 2022, 10, e05367.	0.2	3
67	Chimeric antigen receptor T cell structure, its manufacturing, and related toxicities; A comprehensive review. Advances in Cancer Biology Metastasis, 2022, 4, 100035.	1.1	7
68	Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL. Blood, 2022, 139, 3376-3386.	0.6	36
69	Resistance Mechanisms in Pediatric B-Cell Acute Lymphoblastic Leukemia. International Journal of Molecular Sciences, 2022, 23, 3067.	1.8	6
70	Donor T cells for CAR T cell therapy. Biomarker Research, 2022, 10, 14.	2.8	9
71	CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies. Frontiers of Medicine, 2021, 15, 783-804.	1.5	3
72	The safety and efficacy of CAR-T cells in the treatment of prostate cancer: review. Biomarkers, 2022, 27, 22-34.	0.9	1
73	An Overview of Conventional Drugs and Nanotherapeutic Options for the Treatment and Management of Pediatric Acute Lymphoblastic Leukemia. Anti-Cancer Agents in Medicinal Chemistry, 2022, 22, 3050-3061.	0.9	0
74	Allogeneic gamma delta T cells as adoptive cellular therapy for hematologic malignancies. Exploration of Immunology, 0, , 334-350.	1.7	12
75	The current treatment approach to adolescents and young adults with acute lymphoblastic leukemia (AYA-ALL): challenges and considerations. Expert Review of Anticancer Therapy, 2022, 22, 845-860.	1.1	2

#	ARTICLE	IF	CITATIONS
76	Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma. <i>Blood</i> , 2022, 140, 851-860.	0.6	28
77	Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	33
78	A Novel Bispecific T-Cell Engager (CD1a x CD3 μ) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells. <i>Cancers</i> , 2022, 14, 2886.	1.7	9
79	Molecular Therapy in Myasthenia Gravis. <i>Touch Reviews in Neurology</i> , 2022, 18, 49.	0.1	0
80	Receptor Guanylyl Cyclase C and Cyclic GMP in Health and Disease: Perspectives and Therapeutic Opportunities. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	10
81	Leveraging gene therapy to achieve long-term continuous or controllable expression of biotherapeutics. <i>Science Advances</i> , 2022, 8, .	4.7	7
82	RCMNet: A deep learning model assists CAR-T therapy for leukemia. <i>Computers in Biology and Medicine</i> , 2022, 150, 106084.	3.9	10
83	Chemotherapy induces plasmatic antioxidant changes in pediatric patients with acute lymphoid leukemia B that correlate to disease prognosis. <i>Current Research in Immunology</i> , 2022, 3, 228-233.	1.2	1
85	Next generations of CAR-T cells - new therapeutic opportunities in hematology?. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	24
86	The pathogenesis, diagnosis, prevention, and treatment of CAR-T cell therapy-related adverse reactions. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	7
87	Comparative analysis of the variability of the human leukocyte antigen peptide-binding pockets in patients with acute leukaemia. <i>British Journal of Haematology</i> , 2023, 200, 197-209.	1.2	4
88	Mature B and plasma cell flow cytometric analysis: A review of the impact of targeted therapy. <i>Cytometry Part B - Clinical Cytometry</i> , 2023, 104, 224-242.	0.7	3
89	Manganese immunotherapy for treating osteosarcoma: Glycosylating 1V209 anchored MnO ₂ nanosheets prompt pro-inflammatory macrophage polarization. <i>Nano Today</i> , 2023, 48, 101670.	6.2	5
90	Mild blurry vision as the initial presentation of central nervous system relapses of acute lymphoblastic leukemia: a case report. <i>BMC Ophthalmology</i> , 2022, 22, .	0.6	0
91	Activation priming and cytokine polyfunctionality modulate the enhanced functionality of low-affinity CD19 CAR T cells. <i>Blood Advances</i> , 2023, 7, 1725-1738.	2.5	7
92	Hematological Problems in Pediatric Surgery. , 2023, , 119-144.		0
93	Chimeric antigen receptor T (<sc>CAR</sc>) cells: Novel cell therapy for hematological malignancies. <i>Cancer Medicine</i> , 2023, 12, 7844-7858.	1.3	15
94	Single-Cell Transcriptomics Reveals Immune Reconstitution in Patients with R/R T-ALL/LBL Treated with Donor-Derived CD7 CAR-T Therapy. <i>Clinical Cancer Research</i> , 2023, 29, 1484-1495.	3.2	6

#	ARTICLE	IF	CITATIONS
95	Extracorporeal membrane oxygenation in adults receiving haematopoietic cell transplantation: an international expert statement. <i>Lancet Respiratory Medicine</i> , 2023, 11, 477-492.	5.2	7
96	All-trans retinoic acid improves NSD2-mediated RAR \pm phase separation and efficacy of anti-CD38 CAR T-cell therapy in multiple myeloma. , 2023, 11, e006325.		3
97	Targeting CD19 and CD22 with CAR-T cell therapy in acute lymphoid leukemia. , 0, 36, 918-923.		0
98	Highly sensitive single tube B α lymphoblastic leukemia/lymphoma minimal/measurable residual disease test robust to surface antigen directed therapy. <i>Cytometry Part B - Clinical Cytometry</i> , 2023, 104, 279-293.	0.7	5
99	Muramyl dipeptide CD10 monoclonal antibody immunoconjugates inhibited acute leukemia in nude mice. <i>Bioscience Reports</i> , 0, , .	1.1	0
101	The clinical application of immuno-therapeutics. , 2024, , 237-288.e7.		0
103	Stem Cell Transplant for Acute Lymphoblastic Leukemia. , 2023, , 479-500.		0
104	Updated Clinical Perspectives and Challenges of Chimeric Antigen Receptor-T Cell Therapy in Colorectal Cancer and Invasive Breast Cancer. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2023, 71, .	1.0	1
109	Overcoming toxicity challenges in CAR-T therapy: mechanisms and mitigation strategies. , 2024, , .		0